Kolltan Pharmaceuticals, Inc., a privately held biopharmaceutical company, today announced a license and research agreement with The Children's Hospital of Philadelphia (CHOP) to commence a collaboration with Yaël Mossé, M.D, an internationally recognized clinician and scientist for her work studying the causes and novel therapeutic approaches for the treatment of children diagnosed with neuroblastoma.
“We are excited to begin our scientific effort with CHOP and look forward to our collaboration focused on this novel receptor tyrosine kinase target for the treatment of cancers that affect many children”
"We are excited to begin our scientific effort with CHOP and look forward to our collaboration focused on this novel receptor tyrosine kinase target for the treatment of cancers that affect many children", commented Jerry McMahon, Ph.D., Kolltan's President and Chief Executive Officer. "This collaboration is representative of Kolltan's work with leading academic researchers and clinicians and exemplifies our commitment to creating novel biologic products for cancers in select cancer types where receptor tyrosine kinases play a key role."
Dr. Mossé stated, "While small molecule inhibition of ALK remains a promising strategy for the subset of patients with an ALK mutation or amplification, development of ALK-targeted immunotherapy or antibody-drug conjugates also may enhance the response in those cells. We believe immunotherapy and ADCs may provide a therapeutic option for the majority of patients with high-risk disease given the widespread expression of ALK on the cell surface of most neuroblastoma tumors."
Microfluidic chips advance neurodegenerative disease research